Selective Laser Trabeculoplasty is clinically proven
to treat glaucoma by safely and effectively reducing
intraocular pressure in a single, office procedure.1,3,5
SLT can be an effective adjunct to medication
therapy or used as a primary treatment to reduce or
eliminate the need for topical glaucoma medications,
along with their common systemic side effects.4
SLT has the potential to save your patients
thousand of dollars in prescription medication
costs and improve compliance.
SLT - Simply visionary!
SLT: Proven Equivalent to Latanoprost at Lowering IOP*
 |
The Selecta II 532 nm wavelength is highly
absorbed by melanin and can selectively
target pigmented cells while preserving
surrounding tissue. This produces a biological
effect on the trabecular meshwork which
stimulates the body’s natural mechanisms to
enhance aqueous outflow and reduce IOP.6 |
*M Nagar, A Ogunyomade, D P S O’Brart, F Howes, and J Marshall.
A randomised, prospective study comparing selective laser trabeculoplasty
with latanoprost for the control of intraocular pressure in ocular hypertension
and open angle glaucoma. Br. J. Ophthalmology, Nov 2005; 89:1413 - 1417.
|
Compare Thermal Effect of SLT to ALT |
 |
 |
SLT
SLT protects trabecular
meshwork against thermal
or coagulative effects
by selectively targeting
only the pigmented
cells and preserving
surrounding tissue.8 |
ALT
ALT causes thermal
injury and coagulative
damage to trabecular
meshwork, making
repeat treatment
difficult.8 |
Advantages of Selecta II for SLT Laser Therapy
- Proven to reduce IOP 1
- No systemic side effects 2
- A single treatment therapy 3
- Effective as primary,
adjunct or repeat therapy 4
- Safe, office-based procedure 5
- Protects trabecular meshwork 6
- Improves patient compliance
- Medicare reimbursed 7
Lasers
Additional Information
References
1) P Lanzetta, U Menchini, G Virgili.
Immediate intraocular pressure response
to selective laser trabeculoplasty. Fr. J.
Ophthalmol., Jan 1999; 83:29-32.
2) Latina MA, Sibayan SA, Shin DH, Noecker RJ,
Marcellino G. Q-switched 532-nm Nd:YAG laser
trabeculoplasty (Selective Laser Trabeculoplasty).
Ophthalmology 1998;105:2082-2090.
3) FDA clearance; 510(k) Number K021550
4) S. Melamed MD, g.J. Ben Simon MD,
H. Levkovitch-Verbin MD. Selective Laser
Trabeculoplasty as Primary Treatment for Openangle
Glaucoma. A Prospective, Nonrandomized
Pilot Study. Arch Ophthalmol., 2003; 121:957-960.
5) Noecker RJ, Kramer TR. Comparison of the
acute morphologic changes after selective laser
trabeculoplasty and argon laser trabeculoplasty
in human eye bank eyes. Ophthalmology, Apr 2001;
108(4):773-9.
6) Alvarado JA, Latina MA, Damji KF, Katz LJ. The
Science Underlying Selective Laser Trabeculoplasty.
Ophthalmology Management, June 2002.
7) Centers for Medicare and Medicaid Services
8) Noecker RJ, Kramer TR. Comparison of the acute
morphologic changes after selective laser trabeculoplasty
and argon laser trabeculoplasty in human eye
